Kleiner Device Labs (KDL) today announced that it will host a meeting room at McKinsey & Company’s Early Stage Investor Conference on the morning of Wednesday, June 22 as part of the event’s HealthTech track.
| INCLINE VILLAGE, Nev., June 16, 2022 /PRNewswire/ -- Kleiner Device Labs (KDL) today announced that it will host a meeting room at McKinsey & Company’s Early Stage Investor Conference on the morning of Wednesday, June 22 as part of the event’s HealthTech track. Investors interested in talking with KDL may find more information and registration at McKinsey’s conference web site here.
“We are excited to participate in McKinsey & Company’s conference to meet prospective investors for future funding opportunities,” said Kleiner Device Labs founder and CEO, Jeff Kleiner MD. KDL is in the midst of launching its next product, the KG2TM SurgeTM flow-thru interbody system, which employs the company’s proprietary flow-thru technology to streamline the implant delivery, positioning and grafting processes for TLIF and PLIF spinal fusion procedures. This brings important outcome and cost improvements to spinal fusion surgeries. For KG2 videos, technical specifications, instructions for use, or clinical efficacy information, please go to the company’s web site. About Kleiner Device Labs Kleiner Device Labs is creating new instruments and devices to advance minimally invasive spine surgery and improve outcomes and costs. Kleiner Device Labs is headquartered in Incline Village, Nevada. KG and Surge are trademarks of Kleiner Device Labs. Sales and Surgeon Contact: Media Contact: Investor Contact: MKT-00010-32 Rev 1
SOURCE Kleiner Device Labs |
View original content to download multimedia:
